# Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

> **NCT01188109** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 25 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01188109
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188109, "Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01188109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*